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tumor metastasis to the pancreas: a rare case
with seven-year follow-up
Lin Shi1,2, Zhanlin Guo3* and Xinlin Wu4Abstract: There are only nine primitive neuroectodermal tumor (PNET) cases that have arisen in lung parenchyma
without pleural or chest wall involvement in the literature. Here, we present a long–term survival case of pulmonary
PNET. A pulmonary mass was detected in a 19-year-old man on a chest radiograph and computed tomography
image. At the three-year follow-up, the mass had enlarged in diameter by two-fold. The lesion was resected via
lower left lobectomy. Histologically, the tumor was composed of uniform cells with round nuclei and scanty
cytoplasm arranged in lobules with rosettes and pseudorosettes formation. Immunohistochemically, the tumor was
positive for CD99, vimentin, neuron specific enolase and chromogranin A, and negative for cytokeratins, CD3,
desmin, and leukocyte common antigen. Pancreatic metastasis occurred sixteen months after the first surgery,
which was managed by pancreatectomy. The patient has survived seven years after the mass was initially detected,
and four years after the first lobectomy.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1500847644913244
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Primitive neuroectodermal tumors (PNETs), first de-
scribed by Hart and Earle in 1973 [1], belong to the
group of highly malignant neoplasms and have a ten-
dency toward early metastasis. This rare neoplasm is
more prevalent in children and adolescents than in
adults, as well as in the central than the peripheral ner-
vous system. Peripheral PNETs (pPNETs) usually involve
bone or soft tissues but have also been discovered in a
variety of other organs, such as the kidney, urinary blad-
der, and heart [2-4]. Reports of pPNETs that arise in the
lung parenchyma without pleural or chest wall involve-
ment are extremely rare. Herein, we report an additional
case of primary PNET in the lung, which then metasta-
sized to the pancreas.* Correspondence: nmggzl@163.com
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In October 2005, a mass in the left lower lung lobe of a
19-year-old male was detected on a chest radiograph
and a computed tomography (CT) image during a rou-
tine health examination (Figure 1a, b). Because the pa-
tient was young and asymptomatic, and since the CT
image indicated a benign tumor, a lung biopsy was not
performed at the time. Physicians then recommended
the patient for semi-annual follow-up.
At the follow-up two-and-a-half years later, an imaging
study showed the invariable lung tumor. At the year 3
follow-up, the mass was found to have enlarged remarkably.
The patient was admitted to our hospital in September
2008 for further evaluation of the lung mass. A chest
radiograph and CT scan showed a well-circumscribed
tumor with a diameter of 5.0 cm in the lateral basal
segment of the left lung (Figure 1c, d), but did not de-
tect any bilateral hilar lymphadenopathy. A bronchos-
copy showed no abnormal results. Standard staging
procedures, including brain magnetic resonance im-
aging (MRI), abdominal ultrasonography, and bone
scintigraphy, did not detect distant metastasis.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Chest radiographs and CT scans of lung and pancreas. a) Chest radiograph showing a mass in the left lung (October 2005).
b) Chest CT showing a well-defined solid mass in the lower lobe of the left lung (October 2005). c) Chest radiograph showing an enlarged
mass in the left lung (September 2008). d) Chest CT showing an enlarged mass in the lower lobe of the left lung (September 2008).
e) Contrast-enhanced CT showing a huge solid mass with cystic areas originating from the pancreas.
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lymph node dissection was ordered. During the operation,
the surgeon discovered a well-defined 5.5 cm × 5.0 cm
solid mass in the parenchyma of the lower lobe of the left
lung, without pleural or chest wall involvement. Micro-
scopic analysis of the resected tissue revealed that the
tumor was composed of small, round cells with incon-
spicuous cytoplasm and arranged in diffuse or compact
sheets or lobules (Figure 2a). Immunohistochemical stain-
ing showed that the tumor cells were strongly positive for
vimentin and CD99 (Figure 2b), focally positive for neuron
specific enolase (NSE) and chromogranin A (CgA), and
negative for cytokeratins, CD3, desmin, and leukocyte
common antigen (LCA). Immunophenotype analysis ruled
out lymphoma, desmoplastic small round cell tumor,neuroblastoma, small-cell carcinoma, rhabdomyosarcoma,
and monophasic synovial sarcoma. Therefore, the postop-
erative pathologic diagnosis was PNET of the lung.
The subsequent pathology indicated clear surgical mar-
gins and pleura and lymph nodes free of tumor cells. The
postoperative course was uneventful. The patient refused
adjunct radiation or chemotherapy after the initial surgery,
but participated in regular follow-up examinations.
After a 16-month disease-free period, the patient
complained of several episodes of a dull ache in the upper
right quadrant of the abdomen. The patient was admitted
to our hospital for further evaluation in February 2010.
An ultrasonography and contrast-enhanced CT scan of
the abdomen revealed a 3.5 cm × 4.0 cm mass in the pan-
creatic head (Figure 1e). The mass had solid and cystic
Figure 2 Histologic features of the tumor in the lung and pancreas. a) The pulmonary tumor cells had round or oval nuclei, a fine
chromatin pattern, and indistinct cytoplasm and nucleoli. Mitotic activity was very high (HE, 400×). b) The pulmonary tumor cells showed
a consistent and strong membranous expression of CD99 (SP, 400×). c) Diffusely infiltrative tumor cells were present in the pancreas
parenchyma (HE, 200×).
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surrounding pancreas parenchyma. Laparotomy showed a
3.0 cm × 4.0 cm solid and cystic mass on the surface of
the uncinate process of the pancreas. The boundary be-
tween the mass and pancreas parenchyma was obscure
and the mass appeared unencapsulated. An en bloc resec-
tion of the mass was accomplished through the standard
Whipple procedure [5]. Diffuse infiltrative tumor cells
were present in the surrounding tissue (Figure 2c). Immu-
nohistochemical staining of the tumor cells confirmed
strong membranous expression of CD99 and focal expres-
sions of vimentin and synaptophysin.
The immunophenotyping results and patient history of
pulmonary PNET indicated a postoperative pathologic
diagnosis of metastatic pancreatic PNET. Again, the pa-
tient refused adjunct radiation and chemotherapy. To
date, no evidence of tumor recurrence or metastasis has
been found. The patient has survived seven years after
the mass was initially detected, and four years after the
first radical resection.
Discussion
pPNETs belong to the family of “small round cell tu-
mors” that show varying degrees of neuroectodermal dif-
ferentiation and are derived from cells originating from
the neural crest [6] and are characterized by a specific
chromosomal translocation, t(11;22)(q24;q12), in most
cases. Among the reported cases of PNET, tumors in-
volving the thoracopulmonary region were first reported
as “malignant small cell tumors of the thoracopulmonary
region in childhood” by Askin et al. in 1979, which led
to these tumors being referred to as Askin’s tumors [7].
Conventional light microscopy analysis of PNETs
shows undifferentiated small, round cells with uniform,
unconspicuous nuclei and scanty cytoplasm arranged in lob-
ules with rosettes and pseudorosettes formation; in addition,
there is little or no stroma. Immunohistochemically, PNETs
are positive for CD99 antigen, but CD99 immunostaining isnot specific and the results must be interpreted in combin-
ation with other findings. T lymphoblastic lymphoma,
poorly differentiated synovial sarcomas, stromal tumors,
and rare rhabdomyosarcoma may show CD99 positivity.
Vimentin stains most tumor cells and neural markers, such
as NSE, and is frequently expressed by tumor cells [6].
Cytokeratin-positive staining has also been reported in
some cases of primitive neuroectodermal tumors [6].
To diagnose a tumor as PNET, it should display small
round cells forming rosette and pseudorosettes, and
should be positive for at least two of the neural
markers. Ultrastructural analysis usually shows PNET
cells to have complex cytoplasmic processes, microtu-
bules, and few neurosecretory granules. The following
chromosomal translocations have been associated with
PNET specimens: t(21;22)(q22;q12), t(11;22)(q24;q12),
t(7;22)(p22;q12), and t(7;22)(q22;q12) [8]. Thus, the
diagnosis of PNET necessitates histopathological, im-
munohistochemical, ultrastructural, and, if possible,
genetic analyses.
The differential diagnosis of PNETs includes neuroblast-
oma, lymphoma, small-cell carcinoma, rhabdomyosar-
coma, monophasic synovial sarcoma, and desmoplastic
small round cell tumor, all of which are indistinguishable
by conventional light microscopy [6]. However, due to the
different prognostic characteristics and therapeutic sched-
ules for each of these tumor types, differential diagnoses
are essential. Immunohistochemical positivity for CD99,
NSE, synaptophysine, and chromogranine A are very use-
ful in differential diagnosis. Furthermore, the presence of
Homer-Wright rosettes are typical for neuroblastomas,
which are also positive for NSE, synaptophysine, and
chromogranine A, but negative for CD99. LCA positivity
supports the diagnosis of lymphoma, but T cell lympho-
blastic lymphoma may be negative for LCA and positive
for CD99 and CD3. Small-cell carcinoma is almost always
positive for cytokeratin, while rhabdomyosarcoma is posi-
tive for desmin, actin, myoglobulin, and monophasic
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The desmoplastic small round cell tumor is characterized
by sharply circumscribed nests or clusters of small, undif-
ferentiated cells surrounded by a desmoplastic stroma, and
show positivity for cytokeratin and desmin, but negativity
for CD99. Therefore, the phenotypes observed in our case,
i.e., positive expression of CD99, vimentin, NSE, and
synaptophysin, and negative expression of cytokeratins,
CD3, desmin, and LCA, are highly suggestive of a pulmon-
ary PNET [3,9-11].
Despite the patient’s history of pulmonary PNET and
imaging findings that were consistent with primary pan-
creatic cancer, we initially suspected primary serous cystic
pancreatic neoplasm because metastasis of a PNET to the
pancreas had never been previously reported. However,
the patient’s histological findings indicated no transition
had occurred from the pancreas to the neoplastic tissue.
In addition, there were no clinical signs of chronic pan-
creatitis in the surrounding parenchyma. Considering
the expression of CD99, NSE, and synaptophysine, as
well as the primary pulmonary PNET, we believed the
findings strongly supported a diagnosis of metastatic pan-
creatic PNET.
According to the literature, there have only been nine
reported cases of PNET originating from the lung with-
out pleural or chest wall involvement [9,12-17]. Ages of
the reported patients have ranged between 8 to 67 years,
with a mean age of 33 years. There is a slight male pre-
dominance, with the male:female ratio being 5:4. Five of
the cases originated from the left lung and four from the
right. Despite treatment with various combinations of
surgery, chemotherapy, and radiation therapy, the sur-
vival rate in the previous reports was poor; typically, the
two-year survival rate after operation is 33.3%. Of the
nine reported cases, seven were followed-up; four were
alive without disease at eight months, 16 months, 22 -
months and two years after surgery, and three had died
at three months, two years, and two years after oper-
ation due to local recurrence or widespread metastatic
disease. Furthermore, the predominating metastatic sites
are the lungs, adrenal glands, and ovaries. In our case,
no adjunct radiation or chemotherapy was given after
the initial surgery, due to patient refusal. However, re-
currence was detected at sixteen months after the first
resection and appeared as a metastasis to the pancreas.
The patient underwent the second radical surgical resec-
tion of the metastatic tumor. Adjunct radiation or
chemotherapy again refused by the patient after the sec-
ond surgery. To date, no evidence of tumor recurrence
or metastasis has emerged. The patient has survived 32 -
months after the second surgery. The long-term survival
of the patient may have been a result of the two radical
surgeries alone, but we believe that his prognosis would
have been better if the lung biopsy was performedpromptly in October 2005. We speculate that close
follow-up with immediate surgical intervention when
required may have helped to prolong the survival of our
case [18].
Conclusion
We reported a rare case in which a primary pulmonary
primitive neuroectodermal tumor metastasized to the
pancreas. The primary and metastatic tumors were
resected respectively, and no adjunct radiation or
chemotherapy was given before or after the two surgical
procedures. This newly described PNET patient has the
longest survival (seven years) and the longest post-
operational follow-up period (four years) of all the cases
reported in the literature to date. We speculate that
close follow-up with immediate surgical intervention
when required may have helped to prolong the survival
of our case.
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